APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR T-Cell-Based Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CAR T-Cell-Based Drug Market Analysis and Forecast 2026-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchCAR T-Cell-Based Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR T-Cell-Based Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal CAR T-Cell-Based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR T-Cell-Based Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR T-Cell-Based Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global CAR T-Cell-Based Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CAR T-Cell-Based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CAR T-Cell-Based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CAR T-Cell-Based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CAR T-Cell-Based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CAR T-Cell-Based Drug include J & J, Novartis, Gilead Sciences, Bristol-Myers Squibb, Sorrento Therapeutics, Mustang Bio, JW Therapeutics, FOSUNKite and Celyad, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CAR T-Cell-Based Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CAR T-Cell-Based Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for CAR T-Cell-Based Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CAR T-Cell-Based Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CAR T-Cell-Based Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CAR T-Cell-Based Drug revenue, projected growth trends, production technology, application and end-user industry.

CAR T-Cell-Based Drug Segment by Company

J & J

Novartis

Gilead Sciences

Bristol-Myers Squibb

Sorrento Therapeutics

Mustang Bio

JW Therapeutics

FOSUNKite

Celyad

Cellectis

CARsgen Therapeutics

Bluebird Bio

Autolus Therapeutics

Allogene Therapeutics

CAR T-Cell-Based Drug Segment by Type

CD19-targeted

BCMA-targeted

CAR T-Cell-Based Drug Segment by Application

Lymphoma

Multiple Myeloma

CAR T-Cell-Based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR T-Cell-Based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR T-Cell-Based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR T-Cell-Based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CAR T-Cell-Based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CAR T-Cell-Based Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CAR T-Cell-Based Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CAR T-Cell-Based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CD19-targeted Major Player Table 3. BCMA-targeted Major Player Table 4. Global CAR T-Cell-Based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Lymphoma Major Player Table 6. Multiple Myeloma Major Player Table 7. CAR T-Cell-Based Drug Industry Trends Table 8. CAR T-Cell-Based Drug Industry Drivers Table 9. CAR T-Cell-Based Drug Industry Opportunities and Challenges Table 10. CAR T-Cell-Based Drug Industry Restraints Table 11. Global CAR T-Cell-Based Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global CAR T-Cell-Based Drug Market Size by Region (2021-2026) & (US$ Million) Table 13. Global CAR T-Cell-Based Drug Market Share by Region (2021-2026) Table 14. Global CAR T-Cell-Based Drug Market Size by Region (2027-2032) & (US$ Million) Table 15. Global CAR T-Cell-Based Drug Market Share by Region (2027-2032) Table 16. Global CAR T-Cell-Based Drug Revenue by Players (US$ Million) & (2021-2026) Table 17. Global CAR T-Cell-Based Drug Revenue Market Share by Players (2021-2026) Table 18. Global CAR T-Cell-Based Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global CAR T-Cell-Based Drug Key Players Headquarters & Area Served Table 20. Global CAR T-Cell-Based Drug Players, Product Type & Application Table 21. Global CAR T-Cell-Based Drug Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global CAR T-Cell-Based Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global CAR T-Cell-Based Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global CAR T-Cell-Based Drug Revenue by Type (2021-2026) & (US$ Million) Table 26. Global CAR T-Cell-Based Drug Revenue by Type (2027-2032) & (US$ Million) Table 27. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2021-2026) Table 28. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2027-2032) Table 29. Global CAR T-Cell-Based Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CAR T-Cell-Based Drug Revenue by Application (2021-2026) & (US$ Million) Table 31. Global CAR T-Cell-Based Drug Revenue by Application (2027-2032) & (US$ Million) Table 32. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2021-2026) Table 33. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2027-2032) Table 34. J & J Company Information Table 35. J & J Business Overview Table 36. J & J CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. J & J CAR T-Cell-Based Drug Product Portfolio Table 38. J & J Recent Development Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Novartis CAR T-Cell-Based Drug Product Portfolio Table 43. Novartis Recent Development Table 44. Gilead Sciences Company Information Table 45. Gilead Sciences Business Overview Table 46. Gilead Sciences CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Gilead Sciences CAR T-Cell-Based Drug Product Portfolio Table 48. Gilead Sciences Recent Development Table 49. Bristol-Myers Squibb Company Information Table 50. Bristol-Myers Squibb Business Overview Table 51. Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio Table 53. Bristol-Myers Squibb Recent Development Table 54. Sorrento Therapeutics Company Information Table 55. Sorrento Therapeutics Business Overview Table 56. Sorrento Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 58. Sorrento Therapeutics Recent Development Table 59. Mustang Bio Company Information Table 60. Mustang Bio Business Overview Table 61. Mustang Bio CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Mustang Bio CAR T-Cell-Based Drug Product Portfolio Table 63. Mustang Bio Recent Development Table 64. JW Therapeutics Company Information Table 65. JW Therapeutics Business Overview Table 66. JW Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. JW Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 68. JW Therapeutics Recent Development Table 69. FOSUNKite Company Information Table 70. FOSUNKite Business Overview Table 71. FOSUNKite CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. FOSUNKite CAR T-Cell-Based Drug Product Portfolio Table 73. FOSUNKite Recent Development Table 74. Celyad Company Information Table 75. Celyad Business Overview Table 76. Celyad CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Celyad CAR T-Cell-Based Drug Product Portfolio Table 78. Celyad Recent Development Table 79. Cellectis Company Information Table 80. Cellectis Business Overview Table 81. Cellectis CAR T-Cell-Based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Cellectis CAR T-Cell-Based Drug Product Portfolio Table 83. Cellectis Recent Development Table 84. CARsgen Therapeutics Company Information Table 85. CARsgen Therapeutics Business Overview Table 86. CARsgen Therapeutics CAR T-Cell-Based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 88. CARsgen Therapeutics Recent Development Table 89. Bluebird Bio Company Information Table 90. Bluebird Bio Business Overview Table 91. Bluebird Bio CAR T-Cell-Based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Bluebird Bio CAR T-Cell-Based Drug Product Portfolio Table 93. Bluebird Bio Recent Development Table 94. Autolus Therapeutics Company Information Table 95. Autolus Therapeutics Business Overview Table 96. Autolus Therapeutics CAR T-Cell-Based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 98. Autolus Therapeutics Recent Development Table 99. Allogene Therapeutics Company Information Table 100. Allogene Therapeutics Business Overview Table 101. Allogene Therapeutics CAR T-Cell-Based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio Table 103. Allogene Therapeutics Recent Development Table 104. North America CAR T-Cell-Based Drug Revenue by Type (2021-2026) & (US$ Million) Table 105. North America CAR T-Cell-Based Drug Revenue by Type (2027-2032) & (US$ Million) Table 106. North America CAR T-Cell-Based Drug Revenue by Application (2021-2026) & (US$ Million) Table 107. North America CAR T-Cell-Based Drug Revenue by Application (2027-2032) & (US$ Million) Table 108. North America CAR T-Cell-Based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America CAR T-Cell-Based Drug Revenue by Country (2021-2026) & (US$ Million) Table 110. North America CAR T-Cell-Based Drug Revenue by Country (US$ Million) & (2027-2032) Table 111. Europe CAR T-Cell-Based Drug Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe CAR T-Cell-Based Drug Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe CAR T-Cell-Based Drug Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe CAR T-Cell-Based Drug Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe CAR T-Cell-Based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Europe CAR T-Cell-Based Drug Revenue by Country (2021-2026) & (US$ Million) Table 117. Europe CAR T-Cell-Based Drug Revenue by Country (US$ Million) & (2027-2032) Table 118. China CAR T-Cell-Based Drug Revenue by Type (2021-2026) & (US$ Million) Table 119. China CAR T-Cell-Based Drug Revenue by Type (2027-2032) & (US$ Million) Table 120. China CAR T-Cell-Based Drug Revenue by Application (2021-2026) & (US$ Million) Table 121. China CAR T-Cell-Based Drug Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia CAR T-Cell-Based Drug Revenue by Type (2021-2026) & (US$ Million) Table 123. Asia CAR T-Cell-Based Drug Revenue by Type (2027-2032) & (US$ Million) Table 124. Asia CAR T-Cell-Based Drug Revenue by Application (2021-2026) & (US$ Million) Table 125. Asia CAR T-Cell-Based Drug Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia CAR T-Cell-Based Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Asia CAR T-Cell-Based Drug Revenue by Region (US$ Million) & (2021-2026) Table 128. Asia CAR T-Cell-Based Drug Revenue by Region (US$ Million) & (2027-2032) Table 129. SAMEA CAR T-Cell-Based Drug Revenue by Type (2021-2026) & (US$ Million) Table 130. SAMEA CAR T-Cell-Based Drug Revenue by Type (2027-2032) & (US$ Million) Table 131. SAMEA CAR T-Cell-Based Drug Revenue by Application (2021-2026) & (US$ Million) Table 132. SAMEA CAR T-Cell-Based Drug Revenue by Application (2027-2032) & (US$ Million) Table 133. SAMEA CAR T-Cell-Based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. SAMEA CAR T-Cell-Based Drug Revenue by Country (2021-2026) & (US$ Million) Table 135. SAMEA CAR T-Cell-Based Drug Revenue by Country (US$ Million) & (2027-2032) Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. CAR T-Cell-Based Drug Image Figure 2. Global CAR T-Cell-Based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CAR T-Cell-Based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. CD19-targeted Image Figure 5. BCMA-targeted Image Figure 6. Global CAR T-Cell-Based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global CAR T-Cell-Based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Lymphoma Image Figure 9. Multiple Myeloma Image Figure 10. Global CAR T-Cell-Based Drug Market Size (US$ Million) & (2021-2032) Figure 11. Global CAR T-Cell-Based Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global CAR T-Cell-Based Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global CAR T-Cell-Based Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global CAR T-Cell-Based Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global CAR T-Cell-Based Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global CAR T-Cell-Based Drug Revenue Market Share by Type (2021-2032) Figure 18. Global CAR T-Cell-Based Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global CAR T-Cell-Based Drug Revenue Market Share by Application (2021-2032) Figure 21. North America CAR T-Cell-Based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America CAR T-Cell-Based Drug Revenue Share by Type (2021-2032) Figure 23. North America CAR T-Cell-Based Drug Revenue Share by Application (2021-2032) Figure 24. North America CAR T-Cell-Based Drug Revenue Share by Country (2021-2032) Figure 25. United States CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe CAR T-Cell-Based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe CAR T-Cell-Based Drug Revenue Share by Type (2021-2032) Figure 30. Europe CAR T-Cell-Based Drug Revenue Share by Application (2021-2032) Figure 31. Europe CAR T-Cell-Based Drug Revenue Share by Country (2021-2032) Figure 32. Germany CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China CAR T-Cell-Based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China CAR T-Cell-Based Drug Revenue Share by Type (2021-2032) Figure 42. China CAR T-Cell-Based Drug Revenue Share by Application (2021-2032) Figure 43. Asia CAR T-Cell-Based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia CAR T-Cell-Based Drug Revenue Share by Type (2021-2032) Figure 45. Asia CAR T-Cell-Based Drug Revenue Share by Application (2021-2032) Figure 46. Asia CAR T-Cell-Based Drug Revenue Share by Region (2021-2032) Figure 47. Japan CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA CAR T-Cell-Based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA CAR T-Cell-Based Drug Revenue Share by Type (2021-2032) Figure 55. SAMEA CAR T-Cell-Based Drug Revenue Share by Application (2021-2032) Figure 56. SAMEA CAR T-Cell-Based Drug Revenue Share by Country (2021-2032) Figure 57. Brazil CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt CAR T-Cell-Based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • CD19-targeted
  • BCMA-targeted
Applications
  • Lymphoma
  • Multiple Myeloma
Companies covered
  • J & J
  • Novartis
  • Gilead Sciences
  • Bristol-Myers Squibb
  • Sorrento Therapeutics
  • Mustang Bio
  • JW Therapeutics
  • FOSUNKite
  • Celyad
  • Cellectis
  • CARsgen Therapeutics
  • Bluebird Bio
  • Autolus Therapeutics
  • Allogene Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CAR T-Cell-Based Drug Market by Type
  3. 1.2.1 Global CAR T-Cell-Based Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CD19-targeted
  5. 1.2.3 BCMA-targeted
  6. 1.3 CAR T-Cell-Based Drug Market by Application
  7. 1.3.1 Global CAR T-Cell-Based Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Lymphoma
  9. 1.3.3 Multiple Myeloma
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 CAR T-Cell-Based Drug Market Dynamics
  1. 2.1 CAR T-Cell-Based Drug Industry Trends
  2. 2.2 CAR T-Cell-Based Drug Industry Drivers
  3. 2.3 CAR T-Cell-Based Drug Industry Opportunities and Challenges
  4. 2.4 CAR T-Cell-Based Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CAR T-Cell-Based Drug Market Perspective (2021-2032)
  2. 3.2 Global CAR T-Cell-Based Drug Growth Trends by Region
  3. 3.2.1 Global CAR T-Cell-Based Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CAR T-Cell-Based Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global CAR T-Cell-Based Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CAR T-Cell-Based Drug Revenue by Players
  2. 4.1.1 Global CAR T-Cell-Based Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global CAR T-Cell-Based Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CAR T-Cell-Based Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CAR T-Cell-Based Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CAR T-Cell-Based Drug Key Players Headquarters & Area Served
  7. 4.4 Global CAR T-Cell-Based Drug Players, Product Type & Application
  8. 4.5 Global CAR T-Cell-Based Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CAR T-Cell-Based Drug Market CR5 and HHI
  11. 4.6.3 2025 CAR T-Cell-Based Drug Tier 1, Tier 2, and Tier 3
5 CAR T-Cell-Based Drug Market Size by Type
  1. 5.1 Global CAR T-Cell-Based Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CAR T-Cell-Based Drug Revenue by Type (2021-2032)
  3. 5.3 Global CAR T-Cell-Based Drug Revenue Market Share by Type (2021-2032)
6 CAR T-Cell-Based Drug Market Size by Application
  1. 6.1 Global CAR T-Cell-Based Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CAR T-Cell-Based Drug Revenue by Application (2021-2032)
  3. 6.3 Global CAR T-Cell-Based Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 J & J
  2. 7.1.1 J & J Company Information
  3. 7.1.2 J & J Business Overview
  4. 7.1.3 J & J CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 J & J CAR T-Cell-Based Drug Product Portfolio
  6. 7.1.5 J & J Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis CAR T-Cell-Based Drug Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Gilead Sciences
  14. 7.3.1 Gilead Sciences Company Information
  15. 7.3.2 Gilead Sciences Business Overview
  16. 7.3.3 Gilead Sciences CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Gilead Sciences CAR T-Cell-Based Drug Product Portfolio
  18. 7.3.5 Gilead Sciences Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb CAR T-Cell-Based Drug Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Sorrento Therapeutics
  26. 7.5.1 Sorrento Therapeutics Company Information
  27. 7.5.2 Sorrento Therapeutics Business Overview
  28. 7.5.3 Sorrento Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sorrento Therapeutics CAR T-Cell-Based Drug Product Portfolio
  30. 7.5.5 Sorrento Therapeutics Recent Developments
  31. 7.6 Mustang Bio
  32. 7.6.1 Mustang Bio Company Information
  33. 7.6.2 Mustang Bio Business Overview
  34. 7.6.3 Mustang Bio CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Mustang Bio CAR T-Cell-Based Drug Product Portfolio
  36. 7.6.5 Mustang Bio Recent Developments
  37. 7.7 JW Therapeutics
  38. 7.7.1 JW Therapeutics Company Information
  39. 7.7.2 JW Therapeutics Business Overview
  40. 7.7.3 JW Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 JW Therapeutics CAR T-Cell-Based Drug Product Portfolio
  42. 7.7.5 JW Therapeutics Recent Developments
  43. 7.8 FOSUNKite
  44. 7.8.1 FOSUNKite Company Information
  45. 7.8.2 FOSUNKite Business Overview
  46. 7.8.3 FOSUNKite CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 FOSUNKite CAR T-Cell-Based Drug Product Portfolio
  48. 7.8.5 FOSUNKite Recent Developments
  49. 7.9 Celyad
  50. 7.9.1 Celyad Company Information
  51. 7.9.2 Celyad Business Overview
  52. 7.9.3 Celyad CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Celyad CAR T-Cell-Based Drug Product Portfolio
  54. 7.9.5 Celyad Recent Developments
  55. 7.10 Cellectis
  56. 7.10.1 Cellectis Company Information
  57. 7.10.2 Cellectis Business Overview
  58. 7.10.3 Cellectis CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Cellectis CAR T-Cell-Based Drug Product Portfolio
  60. 7.10.5 Cellectis Recent Developments
  61. 7.11 CARsgen Therapeutics
  62. 7.11.1 CARsgen Therapeutics Company Information
  63. 7.11.2 CARsgen Therapeutics Business Overview
  64. 7.11.3 CARsgen Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 CARsgen Therapeutics CAR T-Cell-Based Drug Product Portfolio
  66. 7.11.5 CARsgen Therapeutics Recent Developments
  67. 7.12 Bluebird Bio
  68. 7.12.1 Bluebird Bio Company Information
  69. 7.12.2 Bluebird Bio Business Overview
  70. 7.12.3 Bluebird Bio CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bluebird Bio CAR T-Cell-Based Drug Product Portfolio
  72. 7.12.5 Bluebird Bio Recent Developments
  73. 7.13 Autolus Therapeutics
  74. 7.13.1 Autolus Therapeutics Company Information
  75. 7.13.2 Autolus Therapeutics Business Overview
  76. 7.13.3 Autolus Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Autolus Therapeutics CAR T-Cell-Based Drug Product Portfolio
  78. 7.13.5 Autolus Therapeutics Recent Developments
  79. 7.14 Allogene Therapeutics
  80. 7.14.1 Allogene Therapeutics Company Information
  81. 7.14.2 Allogene Therapeutics Business Overview
  82. 7.14.3 Allogene Therapeutics CAR T-Cell-Based Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Allogene Therapeutics CAR T-Cell-Based Drug Product Portfolio
  84. 7.14.5 Allogene Therapeutics Recent Developments
8 North America
  1. 8.1 North America CAR T-Cell-Based Drug Revenue (2021-2032)
  2. 8.2 North America CAR T-Cell-Based Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America CAR T-Cell-Based Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America CAR T-Cell-Based Drug Revenue by Type (2027-2032)
  5. 8.3 North America CAR T-Cell-Based Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America CAR T-Cell-Based Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America CAR T-Cell-Based Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America CAR T-Cell-Based Drug Revenue by Application (2027-2032)
  9. 8.5 North America CAR T-Cell-Based Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America CAR T-Cell-Based Drug Revenue by Country
  11. 8.6.1 North America CAR T-Cell-Based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CAR T-Cell-Based Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America CAR T-Cell-Based Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe CAR T-Cell-Based Drug Revenue (2021-2032)
  2. 9.2 Europe CAR T-Cell-Based Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe CAR T-Cell-Based Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe CAR T-Cell-Based Drug Revenue by Type (2027-2032)
  5. 9.3 Europe CAR T-Cell-Based Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe CAR T-Cell-Based Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe CAR T-Cell-Based Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe CAR T-Cell-Based Drug Revenue by Application (2027-2032)
  9. 9.5 Europe CAR T-Cell-Based Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe CAR T-Cell-Based Drug Revenue by Country
  11. 9.6.1 Europe CAR T-Cell-Based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CAR T-Cell-Based Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe CAR T-Cell-Based Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China CAR T-Cell-Based Drug Revenue (2021-2032)
  2. 10.2 China CAR T-Cell-Based Drug Revenue by Type (2021-2032)
  3. 10.2.1 China CAR T-Cell-Based Drug Revenue by Type (2021-2026)
  4. 10.2.2 China CAR T-Cell-Based Drug Revenue by Type (2027-2032)
  5. 10.3 China CAR T-Cell-Based Drug Revenue Share by Type (2021-2032)
  6. 10.4 China CAR T-Cell-Based Drug Revenue by Application (2021-2032)
  7. 10.4.1 China CAR T-Cell-Based Drug Revenue by Application (2021-2026)
  8. 10.4.2 China CAR T-Cell-Based Drug Revenue by Application (2027-2032)
  9. 10.5 China CAR T-Cell-Based Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CAR T-Cell-Based Drug Revenue (2021-2032)
  2. 11.2 Asia CAR T-Cell-Based Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia CAR T-Cell-Based Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia CAR T-Cell-Based Drug Revenue by Type (2027-2032)
  5. 11.3 Asia CAR T-Cell-Based Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia CAR T-Cell-Based Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia CAR T-Cell-Based Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia CAR T-Cell-Based Drug Revenue by Application (2027-2032)
  9. 11.5 Asia CAR T-Cell-Based Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia CAR T-Cell-Based Drug Revenue by Country
  11. 11.6.1 Asia CAR T-Cell-Based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CAR T-Cell-Based Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia CAR T-Cell-Based Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CAR T-Cell-Based Drug Revenue (2021-2032)
  2. 12.2 SAMEA CAR T-Cell-Based Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CAR T-Cell-Based Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CAR T-Cell-Based Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA CAR T-Cell-Based Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CAR T-Cell-Based Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CAR T-Cell-Based Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CAR T-Cell-Based Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA CAR T-Cell-Based Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CAR T-Cell-Based Drug Revenue by Country
  11. 12.6.1 SAMEA CAR T-Cell-Based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CAR T-Cell-Based Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CAR T-Cell-Based Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst